Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

Ryan M. Rich, Philip J Rosenfeld, Carmen A. Puliafito, Sander Dubovy, Janet L Davis, Harry W Flynn, Serafin Gonzalez, William J Feuer, Richard C. Lin, Geeta A. Lalwani, Jackie K. Nguyen, Gaurav Kumar

Research output: Contribution to journalArticle

425 Citations (Scopus)

Abstract

PURPOSE: To evaluate the safety and efficacy of intravitreal bevacizumab (Avastin, Genentech Inc.) for the treatment of neovascular age-related macular degeneration (ARMD). METHODS: A retrospective review was performed on consented patients with neovascular ARMD receiving intravitreal bevacizumab therapy. All patients received intravitreal bevacizumab at baseline with additional monthly injections given at the discretion of the treating physician. At each visit, a routine Snellen visual acuity assessment was performed followed by an ophthalmic examination and optical coherence tomography (OCT) imaging. RESULTS: Fifty-three eyes of 50 patients received an intravitreal bevacizumab injection between May and August 2005. Including the month 3 visit, the average number of injections was 2.3 out of a maximum of 4 injections. No serious drug-related ocular or systemic adverse events were identified. Improvements in visual acuity and central retinal thickness measurements were evident by week 1 and continued through month 3. At month 3, the mean visual acuity improved from 20/160 to 20/125 (P<0.001) and the mean central retinal thickness decreased by 99.6 μm (P<0.001). CONCLUSION: Off-label intravitreal bevacizumab therapy for neovascular ARMD was well tolerated over 3 months with improvements in visual acuity and OCT central retinal thickness measurements. While the long-term safety and efficacy of intravitreal bevacizumab remain unknown, these short-term results suggest that intravitreal bevacizumab may be the most cost effective therapy for the treatment of neovascular ARMD.

Original languageEnglish
Pages (from-to)495-511
Number of pages17
JournalRetina
Volume26
Issue number5
DOIs
StatePublished - May 1 2006

Fingerprint

Macular Degeneration
Safety
Visual Acuity
Optical Coherence Tomography
Injections
Therapeutics
Intravitreal Injections
Bevacizumab
Physicians
Costs and Cost Analysis
Pharmaceutical Preparations

Keywords

  • Antibodies
  • Blood pressure
  • Choroidal neovascularization/diagnosis/drug therapy/etiology
  • Injections
  • Intravitreal
  • Macular degeneration/complications/diagnosis/drug therapy
  • Monoclonal/adverse effects/therapeutic use
  • Tomography
  • Visual acuity/drug effects

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. / Rich, Ryan M.; Rosenfeld, Philip J; Puliafito, Carmen A.; Dubovy, Sander; Davis, Janet L; Flynn, Harry W; Gonzalez, Serafin; Feuer, William J; Lin, Richard C.; Lalwani, Geeta A.; Nguyen, Jackie K.; Kumar, Gaurav.

In: Retina, Vol. 26, No. 5, 01.05.2006, p. 495-511.

Research output: Contribution to journalArticle

Rich, Ryan M. ; Rosenfeld, Philip J ; Puliafito, Carmen A. ; Dubovy, Sander ; Davis, Janet L ; Flynn, Harry W ; Gonzalez, Serafin ; Feuer, William J ; Lin, Richard C. ; Lalwani, Geeta A. ; Nguyen, Jackie K. ; Kumar, Gaurav. / Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. In: Retina. 2006 ; Vol. 26, No. 5. pp. 495-511.
@article{b57cbae6729e458da5ee96530e553b33,
title = "Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration",
abstract = "PURPOSE: To evaluate the safety and efficacy of intravitreal bevacizumab (Avastin, Genentech Inc.) for the treatment of neovascular age-related macular degeneration (ARMD). METHODS: A retrospective review was performed on consented patients with neovascular ARMD receiving intravitreal bevacizumab therapy. All patients received intravitreal bevacizumab at baseline with additional monthly injections given at the discretion of the treating physician. At each visit, a routine Snellen visual acuity assessment was performed followed by an ophthalmic examination and optical coherence tomography (OCT) imaging. RESULTS: Fifty-three eyes of 50 patients received an intravitreal bevacizumab injection between May and August 2005. Including the month 3 visit, the average number of injections was 2.3 out of a maximum of 4 injections. No serious drug-related ocular or systemic adverse events were identified. Improvements in visual acuity and central retinal thickness measurements were evident by week 1 and continued through month 3. At month 3, the mean visual acuity improved from 20/160 to 20/125 (P<0.001) and the mean central retinal thickness decreased by 99.6 μm (P<0.001). CONCLUSION: Off-label intravitreal bevacizumab therapy for neovascular ARMD was well tolerated over 3 months with improvements in visual acuity and OCT central retinal thickness measurements. While the long-term safety and efficacy of intravitreal bevacizumab remain unknown, these short-term results suggest that intravitreal bevacizumab may be the most cost effective therapy for the treatment of neovascular ARMD.",
keywords = "Antibodies, Blood pressure, Choroidal neovascularization/diagnosis/drug therapy/etiology, Injections, Intravitreal, Macular degeneration/complications/diagnosis/drug therapy, Monoclonal/adverse effects/therapeutic use, Tomography, Visual acuity/drug effects",
author = "Rich, {Ryan M.} and Rosenfeld, {Philip J} and Puliafito, {Carmen A.} and Sander Dubovy and Davis, {Janet L} and Flynn, {Harry W} and Serafin Gonzalez and Feuer, {William J} and Lin, {Richard C.} and Lalwani, {Geeta A.} and Nguyen, {Jackie K.} and Gaurav Kumar",
year = "2006",
month = "5",
day = "1",
doi = "10.1097/01.iae.0000225766.75009.3a",
language = "English",
volume = "26",
pages = "495--511",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

AU - Rich, Ryan M.

AU - Rosenfeld, Philip J

AU - Puliafito, Carmen A.

AU - Dubovy, Sander

AU - Davis, Janet L

AU - Flynn, Harry W

AU - Gonzalez, Serafin

AU - Feuer, William J

AU - Lin, Richard C.

AU - Lalwani, Geeta A.

AU - Nguyen, Jackie K.

AU - Kumar, Gaurav

PY - 2006/5/1

Y1 - 2006/5/1

N2 - PURPOSE: To evaluate the safety and efficacy of intravitreal bevacizumab (Avastin, Genentech Inc.) for the treatment of neovascular age-related macular degeneration (ARMD). METHODS: A retrospective review was performed on consented patients with neovascular ARMD receiving intravitreal bevacizumab therapy. All patients received intravitreal bevacizumab at baseline with additional monthly injections given at the discretion of the treating physician. At each visit, a routine Snellen visual acuity assessment was performed followed by an ophthalmic examination and optical coherence tomography (OCT) imaging. RESULTS: Fifty-three eyes of 50 patients received an intravitreal bevacizumab injection between May and August 2005. Including the month 3 visit, the average number of injections was 2.3 out of a maximum of 4 injections. No serious drug-related ocular or systemic adverse events were identified. Improvements in visual acuity and central retinal thickness measurements were evident by week 1 and continued through month 3. At month 3, the mean visual acuity improved from 20/160 to 20/125 (P<0.001) and the mean central retinal thickness decreased by 99.6 μm (P<0.001). CONCLUSION: Off-label intravitreal bevacizumab therapy for neovascular ARMD was well tolerated over 3 months with improvements in visual acuity and OCT central retinal thickness measurements. While the long-term safety and efficacy of intravitreal bevacizumab remain unknown, these short-term results suggest that intravitreal bevacizumab may be the most cost effective therapy for the treatment of neovascular ARMD.

AB - PURPOSE: To evaluate the safety and efficacy of intravitreal bevacizumab (Avastin, Genentech Inc.) for the treatment of neovascular age-related macular degeneration (ARMD). METHODS: A retrospective review was performed on consented patients with neovascular ARMD receiving intravitreal bevacizumab therapy. All patients received intravitreal bevacizumab at baseline with additional monthly injections given at the discretion of the treating physician. At each visit, a routine Snellen visual acuity assessment was performed followed by an ophthalmic examination and optical coherence tomography (OCT) imaging. RESULTS: Fifty-three eyes of 50 patients received an intravitreal bevacizumab injection between May and August 2005. Including the month 3 visit, the average number of injections was 2.3 out of a maximum of 4 injections. No serious drug-related ocular or systemic adverse events were identified. Improvements in visual acuity and central retinal thickness measurements were evident by week 1 and continued through month 3. At month 3, the mean visual acuity improved from 20/160 to 20/125 (P<0.001) and the mean central retinal thickness decreased by 99.6 μm (P<0.001). CONCLUSION: Off-label intravitreal bevacizumab therapy for neovascular ARMD was well tolerated over 3 months with improvements in visual acuity and OCT central retinal thickness measurements. While the long-term safety and efficacy of intravitreal bevacizumab remain unknown, these short-term results suggest that intravitreal bevacizumab may be the most cost effective therapy for the treatment of neovascular ARMD.

KW - Antibodies

KW - Blood pressure

KW - Choroidal neovascularization/diagnosis/drug therapy/etiology

KW - Injections

KW - Intravitreal

KW - Macular degeneration/complications/diagnosis/drug therapy

KW - Monoclonal/adverse effects/therapeutic use

KW - Tomography

KW - Visual acuity/drug effects

UR - http://www.scopus.com/inward/record.url?scp=33745782355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745782355&partnerID=8YFLogxK

U2 - 10.1097/01.iae.0000225766.75009.3a

DO - 10.1097/01.iae.0000225766.75009.3a

M3 - Article

C2 - 16770255

AN - SCOPUS:33745782355

VL - 26

SP - 495

EP - 511

JO - Retina

JF - Retina

SN - 0275-004X

IS - 5

ER -